Ex­clu­sive: Khosla Ven­tures leads seed round in mR­NA biotech look­ing to re­verse ag­ing by length­en­ing telom­eres

A tiny biotech start­up called Re­ju­ve­na­tion Tech­nolo­gies is the lat­est to chase a mas­sive am­bi­tion in re­vers­ing ag­ing, a buzzy and of­ten con­tro­ver­sial re­search area emerg­ing in biotech.

Re­ju­ve­na­tion an­nounced Wednes­day it has raised $10.6 mil­lion in a seed round led by Khosla Ven­tures. The Cal­i­for­nia start­up, found­ed by two Stan­ford PhD sci­en­tists, be­lieves now is the right time to de­vel­op drugs that length­en telom­eres, which act like pro­tec­tive caps on the ends of chro­mo­somes. The field has ex­pe­ri­enced plen­ty of ups and downs over the last cou­ple of decades. No biotech has yet to suc­cess­ful­ly de­vel­op a drug tar­get­ing these DNA se­quences.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER